These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 39134188)

  • 81. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Antibody-drug Conjugate Targets, Drugs, and Linkers.
    Teicher BA; Morris J
    Curr Cancer Drug Targets; 2022; 22(6):463-529. PubMed ID: 35209819
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold.
    Matikonda SS; McLaughlin R; Shrestha P; Lipshultz C; Schnermann MJ
    Bioconjug Chem; 2022 Jul; 33(7):1241-1253. PubMed ID: 35801843
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Antibody-drug conjugates: Recent advances in linker chemistry.
    Su Z; Xiao D; Xie F; Liu L; Wang Y; Fan S; Zhou X; Li S
    Acta Pharm Sin B; 2021 Dec; 11(12):3889-3907. PubMed ID: 35024314
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
    Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
    Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Basics and Innovations in Antibody-Drug Conjugates].
    Manabe S
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):681-685. PubMed ID: 39191680
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress.
    Yao HP; Zhao H; Hudson R; Tong XM; Wang MH
    Drug Discov Today; 2021 Aug; 26(8):1857-1874. PubMed ID: 34224904
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
    Edupuganti VVSR; Tyndall JDATDA; Gamble AB
    Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.
    Leverett CA; Sukuru SC; Vetelino BC; Musto S; Parris K; Pandit J; Loganzo F; Varghese AH; Bai G; Liu B; Liu D; Hudson S; Doppalapudi VR; Stock J; O'Donnell CJ; Subramanyam C
    ACS Med Chem Lett; 2016 Nov; 7(11):999-1004. PubMed ID: 27882198
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.
    Boni V; Sharma MR; Patnaik A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-17. PubMed ID: 32315240
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Small Molecule-Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs.
    Zhang J; Hu F; Aras O; Chai Y; An F
    ChemMedChem; 2024 Jun; 19(11):e202300720. PubMed ID: 38396351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.